Details of Drug-Drug Interaction
| Drug General Information (ID: DDI8RH9EMF) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Succinylcholine | Drug Info | Irinotecan (liposomal) | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Analgesics | Antineoplastics | |||||||
| Structure | |||||||||
| Mechanism of Succinylcholine-Irinotecan (liposomal) Interaction (Severity Level: Minor) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of neuromuscular blocking agents Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Succinylcholine | Irinotecan (liposomal) | |||||||
| Mechanism |
Neuromuscular blocking agent Neuronal acetylcholine receptor Antagonist |
Attenuates neuromuscular blockade | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Neuronal acetylcholine receptor | Structure Sequence | |||||||
| Protein Family | Ligand-gated ion channel (TC 1.A.9) family | ||||||||
| Protein Function |
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Anectine (succinylcholine). Glaxo Wellcome, Research Triangle Park, NC. | ||||||||||||||||||
| 2 | Product Information. Camptosar (irinotecan). Pharmacia and Upjohn, Kalamazoo, MI. | ||||||||||||||||||